166 results
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Protocol No
ASTELLAS-7465-CL-0301
Sub Category
Prostate and Urologic Cancers
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Protocol No
RPCI-I-191711
Sub Category
Prostate and Urologic Cancers
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
The CHAARTED2 Trial HSPC Previously Treated With Docetaxel & ADT
Protocol No
ECOG-EA8153-CHAARTED2
Sub Category
Prostate and Urologic Cancers
A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE)
Protocol No
FERRING-000108-PRONOUNCE
Sub Category
Prostate and Urologic Cancers
BeiGene BGB-A317-207: A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms
Protocol No
BEIGENE-A317-207
Sub Category
Hematologic/Blood Related Cancers
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and RucAparib Combination Switch Maintenance following Front-Line Platinum-based Chemotherapy in Ovarian Cancer Patients
To evaluate PFS by Response Evaluation Criteria in Solid Tumors (RECIST), as assessed by the investigator, in molecularly-defined HRD subgroups, using the following parallel comparisons:
- Arm A (oral rucaparib+ intravenous [IV] nivolumab) versus Arm B (oral rucaparib+IV placebo)
- Arm A (oral rucaparib+IV nivolumab) versus Arm D (placebo [oral and IV])
- Arm B (oral rucaparib+IV placebo) versus Arm D (placebo [oral and IV])
- Arm A (oral rucaparib+ intravenous [IV] nivolumab) versus Arm B (oral rucaparib+IV placebo)
- Arm A (oral rucaparib+IV nivolumab) versus Arm D (placebo [oral and IV])
- Arm B (oral rucaparib+IV placebo) versus Arm D (placebo [oral and IV])
Protocol No
GOG-3020-CLOVIS-CO-338-087
Sub Category
Gynecologic Cancers
Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®-TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer
To find out the response rate of Tisotumab Vedotin
Protocol No
GOG-3023-GENMAB-GCT1015-04
Sub Category
Gynecologic Cancers
Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
The purpose of the first part of the safety lead-in
portion is to test the safety of adding atezolizumab to liposomal doxorubicin to find out
what effects, if any, it has on people.
portion is to test the safety of adding atezolizumab to liposomal doxorubicin to find out
what effects, if any, it has on people.
Protocol No
NRG-GY009
Sub Category
Gynecologic Cancers
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infilitrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
TIL (LN-145) followed by IL-2 with Recurrent and/or Metastatic Squamous Cell
Protocol No
IOVANCE-C-145-03-HN
Sub Category
Head and Neck Cancers
Phase I Proteon Vonapantinase 115
The purpose of this phase I trial is to study the effects of vonapanitase administered following angioplasty of distal popliteal, tibial or peroneal artery in patients with peripheral vascular disease blinded and in varied dose amounts
Investigators: Parag J. Patel, MD; Kellie Brown, MD; Brian Lewis, MD; Michael Malinowski, MD; Peter Rossi, MD; Matthew Scheidt, MD; Robert Hieb, MD
Status: Currently enrolling
Sub Category
Vascular Surgery and Vascular Interventional Radiology
A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)
Protocol No
CLOVIS-CO-338-085-ATLAS
Sub Category
Prostate and Urologic Cancers
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer
Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian
Protocol No
LEAP-DEK-DKKI-P204
Sub Category
Gynecologic Cancers
Constellation-CPI-0610-02: A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (done) and Phase 2 (Dose Expansion of CPI- 0610 with and without Ruxolitinib in Patients with MF)
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Protocol No
CONSTELLATION-0610-02
Sub Category
Hematologic/Blood Related Cancers
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects with Selected Relapsed or Refractory Hematological Malignancies
The purpose of this study is to obtain initial information on the safety and tolerability (effects good or bad) of AMG 397, which is taken by mouth (oral), for the treatment of relapsed/refractory (RR) multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL) or acute myeloid leukemia (AML). This study will also look at what doses of AMG 397 are safe for people to take.
Protocol No
AMGEN-20170173
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
The purpose of the first part of this study is to characterize the safety profile of ADCT-301, and find the highest dose level that can be safely taken by patients with different types of lymphoma. The second part of the study is designed to determine if the highest safe dose may be effective in treating lymphoma.
Protocol No
ADCT-301-001
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers